Literature DB >> 7700329

Methylene blue for ifosfamide-associated encephalopathy.

G B Zulian, E Tullen, B Maton.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7700329     DOI： 10.1056/NEJM199505043321817

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  10 in total

Review 1.  Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.

Authors:  T Kerbusch; J de Kraker; H J Keizer; J W van Putten; H J Groen; R L Jansen; J H Schellens; J H Beijnen
Journal:  Clin Pharmacokinet       Date:  2001-01       Impact factor: 6.447

2.  High absolute bioavailability of methylene blue given as an aqueous oral formulation.

Authors:  Ingeborg Walter-Sack; Jens Rengelshausen; Heike Oberwittler; Juergen Burhenne; Olaf Mueller; Peter Meissner; Gerd Mikus
Journal:  Eur J Clin Pharmacol       Date:  2008-09-23       Impact factor: 2.953

3.  Ifosfamide-related encephalopathy in elderly patients : report of five cases and review of the literature.

Authors:  Antonella Brunello; Umberto Basso; Elena Rossi; Micaela Stefani; Cristina Ghiotto; Dario Marino; Gino Crivellari; Silvio Monfardini
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 4.  Cellular and molecular actions of Methylene Blue in the nervous system.

Authors:  Murat Oz; Dietrich E Lorke; Mohammed Hasan; George A Petroianu
Journal:  Med Res Rev       Date:  2011-01       Impact factor: 12.944

5.  Prophylactic treatment of known ifosfamide-induced encephalopathy for chemotherapy with high-dose ifosfamide?

Authors:  Bernd Kasper; Christoph Harter; Julia Meissner; Frauke Bellos; Fatime Krasniqi; Anthony D Ho; Gerlinde Egerer
Journal:  Support Care Cancer       Date:  2004-01-16       Impact factor: 3.603

Review 6.  Encephalopathy after high-dose Ifosfamide: a retrospective cohort study and review of the literature.

Authors:  Karen I Sweiss; Rakesh Beri; Stacy S Shord
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 7.  Alternative mitochondrial electron transfer for the treatment of neurodegenerative diseases and cancers: Methylene blue connects the dots.

Authors:  Shao-Hua Yang; Wenjun Li; Nathalie Sumien; Michael Forster; James W Simpkins; Ran Liu
Journal:  Prog Neurobiol       Date:  2015-11-18       Impact factor: 11.685

Review 8.  Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.

Authors:  J Pelgrims; F De Vos; J Van den Brande; D Schrijvers; A Prové; J B Vermorken
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

9.  Transitioning ifosfamide chemotherapy regimens to the ambulatory setting: reviewing cost savings and safety profile.

Authors:  Cindy Banh; Kendall Valsvik; Alejandra Arredondo; Kassie Notbohm; Emad Elquza; Hani Babiker; Andrew Kraft; Alejandro Recio Boiles; Daniel Persky; Alicia Ortega; Ali McBride
Journal:  Support Care Cancer       Date:  2021-11-26       Impact factor: 3.603

Review 10.  Efficacy and safety of methylene blue in the treatment of malaria: a systematic review.

Authors:  G Lu; M Nagbanshi; N Goldau; M Mendes Jorge; P Meissner; A Jahn; F P Mockenhaupt; O Müller
Journal:  BMC Med       Date:  2018-04-25       Impact factor: 8.775
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.